A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Cenplacel L (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors Celgene Corporation

    • Most Recent Events

    • 27 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Jan 2015 Time frame of primary endpoint changed from 2 years to 1 year as reported by ClinicalTrials.gov record.
    • 14 Jan 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top